Literature DB >> 3528653

Lung diseases after bone marrow transplantation. Results of a clinical, radiological, histological, immunological and lung function study.

H Link, U Reinhard, E Walter, P Wernet, E M Schneider, H Fischbach, M Blaurock, K Wilms, D Niethammer, P Ostendorf.   

Abstract

The case histories of 72 subsequently treated patients - 44 with acute leukemia, 10 with chronic myeloid leukemia, 16 with severe aplastic anemia and 2 with neuroblastoma - were analyzed after bone marrow transplantation (BMT) with respect to pulmonary diseases. Thirty-eight patients suffered from a total of 51 pulmonary complications, which led to death in 20. Of 13 patients, 3 died of bacterial pneumonia, all of them during granulocytopenia; 2 of 6 patients died of fungal pneumonia and 2 out of 3 of a mixed bacterial-mycotic infection. Adult respiratory distress syndrome (ARDS) led to death in 2 patients. A granulocyte count under 500/microliter correlated significantly (P less than 0.002) with the fatal outcome of bacterial, fungal and ARDS pneumonia as well as with bronchitis. Viral pneumonia led to death in 8 of 9 patients; in each there was a significant correlation (P less than 0.05) with graft-versus-host disease (GvHD). Patients with repeated episodes of pulmonary illness had significantly more chronic GvHD (P less than 0.05); several of these patients displayed a reduction in helper T cells and an increase in suppressor T cells in the peripheral blood. The natural killer (NK) cells were reduced and the percentage of activated NK cell level lay between 6% and 69%. B-cells were absent or deficient. These findings explain in part the absence of specific antibody reactivity. Five of these patients also contracted GvHD-associated obstructive bronchiolitis, which did not respond to therapy. Pulmonary infiltrates of unknown origin (including idiopathic interstitial pneumonia) occurred in 8 of the patients (11.1%), with a fatal outcome in 3 patients. Significant changes (P less than 0.05) in lung function after BMT appeared in the form of reduced vital capacity (VC) increased residual volume (RV) and an increase in RV expressed as the percentage of total lung capacity. Pulmonary diseases were the most common complication and cause of death in our patients after BMT.

Entities:  

Mesh:

Year:  1986        PMID: 3528653      PMCID: PMC7095942          DOI: 10.1007/bf01735262

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  71 in total

Review 1.  Bone-marrow transplantation (first of two parts).

Authors:  E Thomas; R Storb; R A Clift; A Fefer; F L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner
Journal:  N Engl J Med       Date:  1975-04-17       Impact factor: 91.245

Review 2.  Lung damage from cytotoxic drugs.

Authors:  C H Collis
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

3.  Factors associated with interstitial pneumonitis after bone-marrow transplantation for acute leukaemia.

Authors:  M M Bortin; H E Kay; R P Gale; A A Rimm
Journal:  Lancet       Date:  1982-02-20       Impact factor: 79.321

4.  Protective environment for marrow transplant recipients: a prospective study.

Authors:  C D Buckner; R A Clift; J E Sanders; J D Meyers; G W Counts; V T Farewell; E D Thomas
Journal:  Ann Intern Med       Date:  1978-12       Impact factor: 25.391

5.  One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation.

Authors:  E D Thomas; C D Buckner; M Banaji; R A Clift; A Fefer; N Flournoy; B W Goodell; R O Hickman; K G Lerner; P E Neiman; G E Sale; J E Sanders; J Singer; M Stevens; R Storb; P L Weiden
Journal:  Blood       Date:  1977-04       Impact factor: 22.113

6.  Cytomegalovirus infection and specific cell-mediated immunity after marrow transplant.

Authors:  J D Meyers; N Flournoy; E D Thomas
Journal:  J Infect Dis       Date:  1980-12       Impact factor: 5.226

7.  Fractionated total body irradiation in marrow transplantation for leukaemia.

Authors:  V Vitale; A Bacigalupo; M T Van Lint; F Frassoni; G Ricci; G Siracusa; G Marziano; M L Vitali; G Scielzo; A Tomassini
Journal:  Br J Haematol       Date:  1983-11       Impact factor: 6.998

8.  Alveolar macrophage dysfunction in human bone marrow transplant recipients.

Authors:  D J Winston; M C Territo; W G Ho; M J Miller; R P Gale; D W Golde
Journal:  Am J Med       Date:  1982-12       Impact factor: 4.965

9.  [Bone marrow transplantation in patients with leukemia].

Authors:  K Wilms; H Link; P Meyer; P Ostendorf; K Schüch; H D Waller; P Wernet; D Niethammer; H Dopfer; W Schneider; F Schunter; G Breitling; W Frommhold; G Seeger; A C Voss
Journal:  Klin Wochenschr       Date:  1982-10-15

10.  Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment.

Authors:  R P Witherspoon; R Storb; H D Ochs; N Fluornoy; K J Kopecky; K M Sullivan; J H Deeg; R Sosa; D R Noel; K Atkinson; E D Thomas
Journal:  Blood       Date:  1981-08       Impact factor: 22.113

View more
  1 in total

Review 1.  [Transplantation of hematopoietic stem cells. I: Definitions, principle indications, complications].

Authors:  H Link; H J Kolb; W Ebell; D K Hossfeld; A Zander; D Niethammer; H Wandt; H Grosse-Wilde; U W Schaefer
Journal:  Med Klin (Munich)       Date:  1997-08-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.